Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase

[1] Schmitt J(2009)Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications [J] Eur Heart J 30 1038-1045

[2] Duray G(2011)Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography [J] PLoS ONE 6 2422-2434

[3] Gersh BJ(2005)Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation [J] Eur Heart J 26 423-434

[4] Kralev S(2009)The registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management [J] Europace 11 1612-1676

[5] Schneider K(2021)2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation [J] Europace 23 4693-4738

[6] Lang S(2020)American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism [J] Blood Adv 4 629-658

[7] Nieuwlaat R(2021)2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee J Am Coll Cardiol 77 78-82

[8] Capucci A(2020)Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: a real-world experience [J] Int J Cardiol 320 373-498

[9] Camm AJ(2021)2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Eur Heart J 42 e125-e151

[10] Nabauer M(2019)2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons [J] Circulation 140 115-123

[1] Schmitt J(2009)Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications [J] Eur Heart J 30 1038-1045

[2] Duray G(2011)Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography [J] PLoS ONE 6 2422-2434

[3] Gersh BJ(2005)Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation [J] Eur Heart J 26 423-434

[4] Kralev S(2009)The registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management [J] Europace 11 1612-1676

[5] Schneider K(2021)2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation [J] Europace 23 4693-4738

[6] Lang S(2020)American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism [J] Blood Adv 4 629-658

[7] Nieuwlaat R(2021)2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee J Am Coll Cardiol 77 78-82

[8] Capucci A(2020)Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: a real-world experience [J] Int J Cardiol 320 373-498

[9] Camm AJ(2021)2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Eur Heart J 42 e125-e151

[10] Nabauer M(2019)2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons [J] Circulation 140 115-123